Chemical Structure, Synthesis, and Acetate Form of Sermorelin Research Peptide | Palmetto Peptides

Chemical Structure, Synthesis, and Acetate Form of Sermorelin Research Peptide

Research Notice: This article covers research on Sermorelin research peptide and Ipamorelin research peptide — available from Palmetto Peptides for laboratory use only.

Research Use Only Disclaimer: All peptides listed on this page are sold exclusively for in vitro and legitimate laboratory research purposes. They are not intended for human consumption, veterinary use, or any clinical application. The information in this article is for scientific and educational reference only and does not constitute medical advice. All research use must comply with applicable federal, state, and institutional regulations. Palmetto Peptides complies fully with all applicable FDA guidelines.

This article is part of the Complete Sermorelin Research Guide.

Research Disclaimer: Sermorelin acetate is sold strictly for in vitro and preclinical laboratory research. It is not approved for human or veterinary use. All content is intended for licensed researchers and scientific professionals.

Last Updated: April 14, 2026 | Reading Time: Approximately 7 minutes | Author: Palmetto Peptides Research Team

Quick Answer

Chemical Structure, Synthesis, and Acetate Form of Sermorelin Research Peptide

Direct answer: Sermorelin is a 29-amino acid synthetic peptide with the sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2, corresponding to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-29 NH2). It is synthesized via solid-phase peptide synthesis (SPPS) and supplied as the acetate salt, which improves aqueous solubility and shelf-life stability compared to the free acid form.

Introduction: Why Structure Matters in Peptide Research

For researchers working with Sermorelin, understanding its chemical identity is more than an academic exercise. Molecular structure determines receptor binding geometry, metabolic stability, solubility, and how the peptide behaves in solution — all of which affect experimental design and result interpretation.

Sermorelin's structure has been extensively characterized since its development in the 1970s and 1980s as a truncated analog of native GHRH. The key discovery was that the first 29 amino acids of GHRH retained full biological activity at the GHRHR receptor, making longer analogs unnecessary for research applications requiring GH secretagogue activity.

Amino Acid Sequence and Notation

Full Sequence

Sermorelin (GHRH 1-29 NH2) has the following amino acid sequence:

In single-letter amino acid code:

The "-NH2" notation at the C-terminus indicates that the peptide terminates in an amide group rather than a free carboxylic acid. This C-terminal amide is a critical structural feature that contributes to:

Enhanced GHRHR binding affinity relative to the free acid form

Improved resistance to carboxypeptidase-mediated degradation

Better mimicry of the native GHRH terminus

Comparison With Native GHRH (1-44)

Amino acid length

29

44

N-terminus

Tyrosine (Tyr, Y)

C-terminus

Arginine-NH2

Leucine-NH2

GHRHR agonist activity

Full agonist

Plasma stability

Low (rapid degradation)

Molecular weight

~3,357 Da

~5,040 Da

Table 1: Structural comparison of Sermorelin vs. native human GHRH.

Molecular Properties

Molecular formula

C149H246N44O42S

~3,357 Da (anhydrous)

CAS number

86168-78-7

Sequence length

29 amino acids

C-terminal modification

Amide (-NH2)

Physical form (lyophilized)

White to off-white powder

Solubility

Freely soluble in water

Storage (lyophilized)

-20°C, protected from light

Table 2: Key molecular properties of Sermorelin acetate.

Why the Acetate Salt Form?

Research-grade Sermorelin is supplied as the acetate salt, formally "Sermorelin acetate," rather than as the free acid. This is a standard practice across the peptide research industry, and understanding why requires a brief look at peptide chemistry.

What Is the Acetate Salt?

During or after solid-phase peptide synthesis, the crude peptide carries a mixture of counterion charges depending on the synthesis and purification process. When the peptide is purified via reverse-phase HPLC using an acetate-buffered system, or when acetate counterion exchange is performed deliberately, the basic amino groups on the peptide (such as the lysine and arginine side chains) are neutralized by acetate anions (CH3COO-).

The result is a more stable, water-soluble form of the peptide that:

Has a well-defined and reproducible chemical composition

Dissolves readily in aqueous solvents (bacteriostatic water, saline)

Exhibits improved shelf life during lyophilized storage

Has predictable counterion ratios that can be accounted for in precise molecular weight calculations

Does the Acetate Affect Biological Activity?

No. The acetate counterions are not covalently bonded to the peptide and dissociate in aqueous solution. Once dissolved, the peptide behaves identically to its free acid or free base forms in terms of GHRHR binding and GH secretion stimulation. Researchers should account for acetate content when making precise molar concentration calculations, as the acetate salt has a slightly higher molecular weight than the free acid.

In plain terms: The acetate is like packaging — it keeps the peptide stable during shipping and storage, but once you open the package (dissolve it in water), the peptide works the same way regardless.

Synthesis: Solid-Phase Peptide Synthesis (SPPS)

Sermorelin is manufactured using Fmoc (fluorenylmethyloxycarbonyl) solid-phase peptide synthesis, the modern standard for research-grade peptide production. Here is an overview of the process:

SPPS Workflow for Sermorelin

Figure 1: Simplified SPPS workflow for Sermorelin acetate production.

Purity Standards in Research-Grade Sermorelin

High-quality research-grade Sermorelin is characterized by:

HPLC purity of 98%+ (peak area %)

Correct molecular weight confirmed by mass spectrometry (MS)

Endotoxin testing (LAL assay) to ensure pyrogen-free status for in vivo studies

Certificate of Analysis (CoA) documenting all quality parameters

For more on what purity testing involves and how to evaluate supplier quality, see our article on Sermorelin purity testing and third-party analysis.

Structural Features That Determine Biological Activity

The N-Terminal Tyrosine

The N-terminal Tyr (tyrosine) at position 1 is essential for GHRHR binding. Studies have shown that modification or deletion of this residue dramatically reduces receptor affinity, making it a critical pharmacophore element.

The Alpha-Helix in the Middle Segment

Computational and NMR studies of GHRH analogs suggest that residues 6-13 adopt an alpha-helical conformation in solution and upon receptor binding. This helical segment is thought to engage a hydrophobic groove in the GHRHR extracellular domain. Sermorelin's sequence preserves this helix-forming region intact.

The C-Terminal Amide

As noted above, the C-terminal -NH2 group enhances receptor binding affinity and metabolic stability. Research comparing amidated and non-amidated GHRH analogs consistently shows superior GHRHR activation by the amidated form.

Methionine at Position 27

Methionine (Met) at position 27 is a chemically reactive residue susceptible to oxidation under certain conditions (UV light, peroxides, high temperature). Oxidized methionine (methionine sulfoxide) at this position reduces biological activity. This is one reason light protection during storage and handling is emphasized in Sermorelin research protocols.

Structural Comparisons: Sermorelin vs. Other GHRH Analogs

29 aa

29 aa (modified)

40 aa

Amide

Key modification

None

DAC / amino acid subs

Extended C-tail

Met oxidation risk

Present (Met27)

Reduced

Present

Water solubility

High

GHRHR selectivity

Table 3: Structural comparison of Sermorelin with related GHRH analogs.

For comparison articles, see Sermorelin vs CJC-1295 and Tesamorelin vs Sermorelin.

Key Research Citations

Guillemin R, et al. "Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly." Science. 1982;218(4572):585-587.

Rivier J, et al. "Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour." Nature. 1982;300(5889):276-278.

Hoffman AR, Crowley WF Jr. "Growth hormone-releasing hormone: structure-activity relationships." Recent Progress in Hormone Research. 1986;42:533-588.

Felix AM, et al. "Synthesis, biological activity and conformational analysis of cyclic GRF analogs." International Journal of Peptide and Protein Research. 1988;32(6):441-454.

Chandrashekhar Y, et al. "Solution conformation of human GHRH(1-29) amide by two-dimensional NMR spectroscopy." Biochemistry. 1991;30(38):9178-9184.

Frequently Asked Questions

What is the molecular weight of Sermorelin?

The free peptide is approximately 3,357 Da. The acetate salt is slightly heavier due to acetate counterions — confirmed in the CoA.

Why is it supplied as the acetate salt?

Acetate counterions improve solubility, storage stability, and compositional reproducibility. They dissociate in solution and do not affect biological activity.

How is it synthesized?

Via Fmoc SPPS, building the 29-residue chain stepwise on solid resin, then purifying by reverse-phase HPLC to 98%+ purity.

What is the CAS number?

86168-78-7 for the base Sermorelin peptide.

Does oxidized Met affect results?

Yes. Oxidized Met27 reduces receptor activity. Protect from light and verify purity before use.